Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)
Authors
Keywords
Drug discovery, Heart failure (HF), Structure-activity relationship (SAR), Soluble guanylate cyclase (sGC) stimulator, Vericiguat
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 149, Issue -, Pages 112894
Publisher
Elsevier BV
Online
2022-04-01
DOI
10.1016/j.biopha.2022.112894
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Soluble guanylate cyclase stimulators and their potential use: a patent review
- (2021) Peter Sandner et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Vericiguat: First Approval
- (2021) Anthony Markham et al. DRUGS
- Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA ( VerICiguaT Global Study in Subjects with HFrEF ) Trial
- (2021) Adriaan A. Voors et al. EUROPEAN JOURNAL OF HEART FAILURE
- Optimal diuretic strategies in heart failure
- (2021) Sarabjeet S. Suri et al. Annals of Translational Medicine
- Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- (2021) Hauke Ruehs et al. CLINICAL PHARMACOKINETICS
- Activation mechanism of human soluble guanylate cyclase by stimulators and activators
- (2021) Rui Liu et al. Nature Communications
- Vericiguat for heart failure and the VICTORIA trial – the dog that didn't bark?
- (2020) Andrew J.S. Coats EUROPEAN JOURNAL OF HEART FAILURE
- Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
- (2020) Michael Boettcher et al. CLINICAL PHARMACOKINETICS
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
- (2020) Muthiah Vaduganathan et al. LANCET
- Novel sGC stimulator improves outcomes in patients with HFrEF
- (2020) Karina Huynh Nature Reviews Cardiology
- Vericiguat — Another Victory for Targeting Cyclic GMP in Heart Failure
- (2020) John C. Burnett NEW ENGLAND JOURNAL OF MEDICINE
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- (2020) Paul W. Armstrong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of heart failure
- (2020) Amy Groenewegen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Heart Failure With Reduced Ejection Fraction
- (2020) Sean P. Murphy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial
- (2020) Ninian N Lang et al. CARDIOVASCULAR RESEARCH
- Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers
- (2020) Michael Boettcher et al. CLINICAL PHARMACOKINETICS
- Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction
- (2020) Paul W. Armstrong et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
- (2020) Héctor Bueno et al. EUROPEAN HEART JOURNAL
- Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records
- (2019) Alicia Uijl et al. EUROPEAN JOURNAL OF HEART FAILURE
- Establishment of rat liver microsome-hydrogel system for in vitro phase II metabolism and its application to study pharmacological effects of UGT substrates
- (2019) Zhe Zhang et al. Drug Metabolism and Pharmacokinetics
- Rationale and Design of the VITALITY-HFpEF Trial
- (2019) Javed Butler et al. Circulation-Heart Failure
- Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology
- (2019) Petar M. Seferovic et al. EUROPEAN JOURNAL OF HEART FAILURE
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- (2019) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension
- (2019) Liang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Soluble guanylate cyclase stimulators and activators: Where are we, where to go?
- (2019) Sijia Xiao et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Characterization of Phase I and Glucuronide Phase II Metabolites of 17 Mycotoxins Using Liquid Chromatography—High-Resolution Mass Spectrometry
- (2019) Irina Slobodchikova et al. Toxins
- Multiplicity of Nitric Oxide and Natriuretic Peptide Signalling in Heart Failure
- (2019) Michael E. J. Preedy et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy
- (2019) Benjamin G Horst et al. eLife
- Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease
- (2019) Nikolaos Tzoumas et al. BRITISH JOURNAL OF PHARMACOLOGY
- cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
- (2019) Andreas Friebe et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
- (2018) Peter Sandner BIOLOGICAL CHEMISTRY
- Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis
- (2018) Michel Komajda et al. EUROPEAN JOURNAL OF HEART FAILURE
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator
- (2018) Paul W. Armstrong et al. JACC-Heart Failure
- Heart failure with preserved ejection fraction in Asia
- (2018) Jasper Tromp et al. EUROPEAN JOURNAL OF HEART FAILURE
- Update on the diagnosis and management of acute heart failure
- (2018) Pishoy Gouda et al. CURRENT OPINION IN CARDIOLOGY
- Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
- (2017) Burkert Pieske et al. EUROPEAN HEART JOURNAL
- August 2017 at a glance: tailored treatment, acute heart failure and cardiac resynchronization
- (2017) Marco Metra EUROPEAN JOURNAL OF HEART FAILURE
- Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure
- (2017) Markus Follmann et al. JOURNAL OF MEDICINAL CHEMISTRY
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN JOURNAL OF HEART FAILURE
- Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
- (2016) Takashi Nakai et al. ACS Medicinal Chemistry Letters
- Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study
- (2015) Xia Zhao et al. CLINICAL PHARMACOKINETICS
- Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence
- (2015) Johannes-Peter Stasch et al. CURRENT OPINION IN PHARMACOLOGY
- Improving outcomes in heart failure: a personal perspective
- (2015) John J.J.V. McMurray EUROPEAN HEART JOURNAL
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction
- (2015) Mihai Gheorghiade et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS
- (2015) Mark-Jean Gnoth et al. Bioanalysis
- Molecular Property Design: Does Everyone Get It?
- (2015) Paul D. Leeson et al. ACS Medicinal Chemistry Letters
- Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
- (2014) John J. V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators
- (2013) Markus Follmann et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators
- (2013) Nils Griebenow et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size
- (2013) Justin S. Bice et al. CARDIOVASCULAR RESEARCH
- The annual global economic burden of heart failure
- (2013) Christopher Cook et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Crystal structure of the Alpha subunit PAS domain from soluble guanylyl cyclase
- (2013) Rahul Purohit et al. PROTEIN SCIENCE
- Predictors of New-Onset Heart Failure
- (2012) Jennifer E. Ho et al. Circulation-Heart Failure
- The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
- (2012) Jennifer C. Irvine et al. PLoS One
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
- (2011) Johannes-Peter Stasch et al. CIRCULATION
- Oxetanes as Versatile Elements in Drug Discovery and Synthesis
- (2010) Johannes A. Burkhard et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Aldosterone Receptor Antagonists
- (2010) Bradley A. Maron et al. CIRCULATION
- Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models
- (2010) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- Oxetanes in Drug Discovery: Structural and Synthetic Insights
- (2010) Georg Wuitschik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension
- (2009) Joachim Mittendorf et al. ChemMedChem
- Nitroglycerin Headache and Nitroglycerin-Induced Primary Headaches From 1846 and Onwards: A Historical Overview and an Update
- (2009) Peer C. Tfelt-Hansen et al. HEADACHE
- Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart
- (2009) Hiroyuki Masuyama et al. HYPERTENSION RESEARCH
- A General and Convenient Catalytic Synthesis of Nitriles from Amides and Silanes
- (2009) Shaolin Zhou et al. ORGANIC LETTERS
- Structure and Signaling Mechanism of Per-ARNT-Sim Domains
- (2009) Andreas Möglich et al. STRUCTURE
- Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers
- (2008) Reiner Frey et al. JOURNAL OF CLINICAL PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now